YK012

Phase 1Small molecule

EExcyte Biopharma Ltd

YK012 is one of 110 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Membranous NephropathyActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Systemic Lupus ErythematosusPhase 1/Phase 2

Active, not recruiting

Membranous NephropathyPhase 1

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Rituxan

Roche

Phase 3

9 3

Medrol

Pfizer

Phase 3

5 4

Stelara

Johnson & Johnson

Phase 3

3 5

Rinvoq

AbbVie

Phase 3

3 6

Gazyva

Roche

Phase 3

2 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 8

Rayos

RRoxane Laboratories

Phase 3

6 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 10

Tylenol

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Efficacy

NCT06565689

Q2 2027

Phase 1/2Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT06580301

Q4 2027

Phase 1Recruiting

Membranous Nephropathy

NCT06982729

Q1 2028

Phase 1Not yet recruiting

Membranous Nephropathy

NCT07234474

Clinical

Trials by Indication[1]

Membranous Nephropathy2 trials

A Phase I Study of YK012 in Primary Membranous Nephropathy

Not yet recruiting·EExcyte Biopharma Ltd·Phase 1·NCT07234474·66 enrolled

Study of YK012 in Primary Membranous Nephropathy

Recruiting·EExcyte Biopharma Ltd·Phase 1·NCT06982729·72 enrolled

Efficacy1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Recruiting·EExcyte Biopharma Ltd·Phase 1·NCT06565689·48 enrolled

B-cell acute lymphoblastic leukemia1 trial

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting·EExcyte Biopharma Ltd·Phase 1/2·NCT06580301·46 enrolled

Systemic Lupus Erythematosus1 trial

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Recruiting·EExcyte Biopharma Ltd·Phase 1/2·NCT07010835·189 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for YK012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YK012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YK012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Excyte Biopharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EExcyte Biopharma Ltd

YK012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Membranous Nephropathy2 trials

Efficacy1 trial

B-cell acute lymphoblastic leukemia1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News